Probity Advisors Inc. Purchases 377 Shares of Moderna, Inc. $MRNA

Probity Advisors Inc. boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 2.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,892 shares of the company’s stock after acquiring an additional 377 shares during the quarter. Probity Advisors Inc.’s holdings in Moderna were worth $411,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Deseret Mutual Benefit Administrators increased its stake in Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock valued at $32,000 after acquiring an additional 392 shares during the last quarter. Blue Sky Capital Consultants Group Inc. grew its stake in shares of Moderna by 3.8% during the first quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company’s stock worth $429,000 after buying an additional 556 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in shares of Moderna by 1.4% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 40,639 shares of the company’s stock worth $1,152,000 after buying an additional 562 shares during the last quarter. Empirical Finance LLC grew its stake in shares of Moderna by 7.3% during the first quarter. Empirical Finance LLC now owns 9,215 shares of the company’s stock worth $261,000 after buying an additional 624 shares during the last quarter. Finally, Xponance Inc. grew its stake in shares of Moderna by 1.4% during the first quarter. Xponance Inc. now owns 45,412 shares of the company’s stock worth $1,287,000 after buying an additional 642 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 0.9%

Shares of Moderna stock opened at $27.49 on Wednesday. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $57.69. The stock has a market cap of $10.74 billion, a price-to-earnings ratio of -3.65 and a beta of 2.01. The company’s fifty day moving average is $25.98 and its 200 day moving average is $27.12.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. During the same quarter in the previous year, the firm posted ($3.33) earnings per share. Moderna’s revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRNA. Evercore ISI set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Barclays decreased their target price on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Morgan Stanley boosted their target price on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Finally, Bank of America decreased their target price on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a research note on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $39.93.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.